

Immunsuppressive Therapie bei neuropathischer Vaskulitis nach dem sicheren Ausschluss von Infektions – Ursachen, oder bei lebensbedrohlichen Krankheits - Zuständen mit Antibiose zugleich.

Immunosuppressive therapy for neuropathic vasculitis after the safe exclusion of infection - causes, or in life-threatening disease – conditions with antibiotics at the same time.

Autoimmun heißt in der Medizin ein **schwerwiegender Krankheitsverlauf** dessen Ursache als **überschießende Reaktion des Immunsystems** gegen körpereigenes Gewebe verstanden wird. **Autoimmune** in medicine is called a **fatal disease** whose cause is understood as **excessive reaction of the immune system** against the body's own tissues.

Immunsuppressive Therapien sind gerechtfertigt bei Autoimmunerkrankungen nachdem eine Infektionsursache sicher ausgeschlossen wurde. Die Behandlung der Infektions-Ursache steht im Vordergrund.

Immunsuppressive therapies are justified in autoimmune diseases after an infectious cause has been ruled out with certainty. Otherwise, the infectious cause must be treated first and foremost.

→ **Immunität** http://www.erlebnishaft.de/danger_model.pdf

Wees SJ, Sunwoo IN, Oh SJ. (1981) Sural nerve biopsy in systemic necrotizing vasculitis. Am J Med 71, 525–32

Kissel JT, Levy RJ, Mendell JR, Griggs RC. (1986) Azathioprine toxicity in neuromuscular disease. Neurology 36, 35–39

[Kollikowski HH](#), [Schwendemann G](#), [Schulz M](#), [Wilhelm H](#), [Lehmann HJ](#) (1988) **Chronic borrelia encephalomyeloradiculitis with severe mental disturbance: immunosuppressive versus antibiotic therapy.** J Neurol. 235(3), 140-2. <http://www.ncbi.nlm.nih.gov/pubmed/3367160>

Somer T, Finegold SM. (1995) **Vasculitides associated with infections**, immunization, and antimicrobial drugs. Clin Infect Dis 20, 1010–36

Murai H, Inaba S, Kira J, Yamamoto A, Ohno M, Goto I. (1995) Hepatitis C virus associated cryoglobulinemic neuropathy successfully treated with plasma exchange. Artif Organs 19, 334–38

Davies L, Spies JM, Pollard JD, McLeod JG. (1996) Vasculitis confined to peripheral nerves. Brain 119, 1441–48

Pascoe MK, Low PA, Windebank AJ, Litchy WJ. (1997) Subacute diabetic proximal neuropathy. Mayo Clin Proc 72, 1123–32

Guillevin L, Cordier JF, Lhote F, et al. (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized **Wegener's granulomatosis**. Arthritis Rheum 40, 2187–98

Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. (1998) Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9, 842–52

Dyck PJB, Engelstad J, Norell J, Dyck PJ. (2000) Microvasculitis in non-diabetic lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety (DLSRPN). J Neuropathol Exp Neurol 59, 525–38

Jayne DR, Chapel H, Adu D, et al. (2000) Intravenous immunoglobulin for **ANCA-associated systemic vasculitis** with persistent disease activity. QJM 93, 433–39

- Dyck PJB, Norell JE, Dyck PJ. (2001) Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. *Can J Neurol Sci* 28, 224–27
- Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. (2003) Nonsystemic vasculitic neuropathy: insights from a clinical cohort. *Neurology* 61, 623–30
- Langford CA (2003) Vasculitis. *J Allergy Clin Immunol* 111, 602–12
- Gold R, Fontana A, Zierz S. (2003) Therapy of neurological disorders in systemic vasculitis. *Semin Neurol* 23, 207–14
- Lamprecht P. (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. *Ann Rheum Dis* 62, 1230–33
- Knight A, Asklung J, Granath F, Sparen P, Ekbohm A (2004) Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. *Ann Rheum Dis* 63, 1307–11
- Tsurikisawa N, Taniguchi M, Saito H, et al. (2004) Treatment of Churg-Strauss syndrome with **high-dose intravenous immunoglobulin**. *Ann Allergy Asthma Immunol* 92, 80–87
- Cronstein BN (2005) **Low-Dose Methotrexate**: A Mainstay in the Treatment of Rheumatoid Arthritis. doi: 10.1124/pr.57.2.3 *Pharmacological Reviews* 57 (2) 163-172
- Pagnoux C, Guillevin L.(2005) Peripheral neuropathy in systemic vasculitides. *Curr Opin Rheumatol* 17, 41–48
- Levy Y, Uziel Y, Zandman G, et al. (2005) Response of vasculitic peripheral neuropathy to **intravenous immunoglobulin**. *Ann NY Acad Sci* 1051, 779–86
- Schaublin G, Michet CJ, Dyck PJB, Burns TM. (2005) An update on the classification and treatment of vasculitic neuropathy. *Lancet Neurol* 4, 853–65
- Guillevin L, Mahr A, Callard P, et al. (2005) Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. *Medicine* 84, 313–22
- Said G, Lacroix C. (2005) Primary and secondary vasculitic neuropathy. *J Neurol* 252, 633–41
- Massengo SA, Bonnet F, Braun C et al. (2005) **Severe neuroborreliosis: the benefit of prolonged high-dose combination of antimicrobial agents with steroids—an illustrative case**. *Diagnostic Microbiology and Infectious Disease* 51, 127–130 <http://www.ncbi.nlm.nih.gov/pubmed/15698718>
- Stasi R, Stipa, Del Poeta G, Amadori S, Newland AC, Provan D. (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with **rituximab**. *Rheumatology (Oxford)* 45, 1432–36
- Dyck PJB, O'Brien P, Bosch P, et al. (2006) The multi-center double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. *Neurology* 66 (suppl 2), A191.
- Gorson KC. (2006) Therapy for vasculitic neuropathies. *Curr Treat Options Neurol* 8, 105–17
- Burns TM, Schaublin GA, Dyck PJ. (2007) Vasculitic neuropathies. *Neurol Clin* 25, 89–113
- Lapraik C, Watts R, Bacon P, et al. (2007) BSR and BHPR guidelines for the management of adults with **ANCA associated vasculitis**. *Rheumatology (Oxford)* 46, 1615–16
- Gorson KC. (2007) Vasculitic neuropathies: an update. *Neurologist* 13, 12–19
- Jayne DRW, Gaskin G, Rasmussen N, et al. (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 18, 2180–88


- Hellmich B, Flossmann O, Gross WL, et al. (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. *Ann Rheum Dis* 66, 605–17
- Metzler C, Miehle N, Manger K, et al. (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in **Wegener's granulomatosis**. *Rheumatology (Oxford)* 46, 1087–91
- De Vita S, Quartuccio L, Fabris M. (2007) Rituximab in mixed cryoglobulinemia: increased experience and perspectives. *Dig Liver Dis* 39 (suppl 1), 122–28
- Scarpato S, Naclerio C, Moscato P, Salvati G. (2007) **Plasmapheresis** in cryoglobulinemic neuropathy: a clinical study. *Dig Liver Dis* 39 (suppl 1), 136–37
- Guillevin L, Pagnoux C. (2007) Therapeutic strategies for systemic necrotizing vasculitides. *Allergol Int* 56, 105–11
- Guillevin L, Pagnoux C. (2007) Indication for plasma exchange for systemic necrotizing vasculitides. *Transfus Apher Sci* 36, 179–85
- Braun A, Neumann T, Oelzner P, et al. (2008) Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. *Rheumatol Int* 28, 503–06
- Collins MP, Periquet MI. (2008) Isolated vasculitis of the peripheral nervous system. *Clin Exp Rheumatol* 26, 118–30
- Pagnoux C, Mahr A, Hamidou MA, et al. (2008) Azathioprine or methotrexate maintenance for **ANCA-associated vasculitis**. *N Engl J Med* 359, 2790–803
- Martinez V, Cohen P, Pagnoux C, et al. (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. *Arthritis Rheum* 58, 308–17
- Faurischou M, Sorensen IJ, Mellekjær L, et al. (2008) Malignancies in **Wegener's granulomatosis**: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 35, 100–05
- Rice J** (2009) [First Drug Shown to Extend Life Span in Mammals](#). In: Massachusetts Institute of Technology (Hrsg.): *Technology Review*. 1–2. [Sirdolimus, Rapamycin, **Rapamune®**]
- De Groot K, Harper L, Jayne DRW, et al. (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 150, 670–80
- Mukhtyar C, Guillevin L, Cid MC, et al. (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis* 68, 310–17
- Visser K, van der Heijde DMFM. (2009) Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. *Clin Exp Rheumatol* 27, 1017–25
- Thaisetthawatkul P, Dyck PJB. (2010) Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. *Curr Treat Options Neurol* 12, 95–99
- Collins MP, Dyck PJB, Gronseth GS, et al. (2010) Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. *J Periph Nerv Syst* 15, 176–84
- Jones RB, Tervaert JWC, Hauser T, et al. (2010) Rituximab versus cyclophosphamide in **ANCA-associated renal vasculitis**. *N Engl J Med* 363, 211–20

- Stone JH, Merkel PA, Spiera R, et al. (2010) Rituximab versus cyclophosphamide for **ANCA-associated vasculitis**. *N Engl J Med* 363, 221–32
- Langford CA. (2010) Vasculitis. *J Allergy Clin Immunol* 125 (2 suppl 2), 216–25
- Dammacco F, Tucci FA, Lauletta G, et al. (2010) Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. *Blood* 116, 343–53
- Saadoun D, Resche Rigon M, Sene D, et al. (2010) Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ ribavirin in hepatitis C-related mixed cryoglobulinemia. *Blood* 116, 326–34
- Saadoun D, Terrier B, Semoun O, et al. (2011) Hepatitis C virus-associated polyarteritis nodosa. *Arthritis Care Res* 63, 427–35
- Ferri C, Cacoub P, Mazzaro C, et al. (2011) Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. *Autoimmun Rev*. 11, 48–55
- Pietrogrande M, De Vita S, Zignego AL, et al. (2011) Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. *Autoimmun Rev* 10, 444–54
- Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. (2011) Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. *Arthritis Rheum* 63, 1435–45
- Pietrogrande M, De Vita S, Zignego AL, et al. (2011) Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. *Autoimmun Rev* 10, 444–54
- Ramos-Casals M, Stone JH, Cid MC, Bosch X. (2012) The cryoglobulinaemias. *Lancet* 379, 348–60
- Harper L, Morgan MD, Walsh M, et al. (2012) Pulse versus daily oral cyclophosphamide for induction of remission in **ANCA-associated vasculitis**: long-term follow-up. *Ann Rheum Dis* 71, 955–60
- Wall N, Harper L. (2012) Complications of long-term therapy for **ANCA-associated systemic vasculitis**. *Nat Rev Nephrol* 8, 523–32
- Smith RM, Jones RB, Jayne DRW. (2012) Progress in treatment of **ANCA-associated vasculitis**. *Arthritis Res Ther* 14, 210
- Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. (2012) Value of **ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis**—a meta-analysis. *Rheumatology (Oxford)* 51, 100–09
- Puéchal X, Gottenberg JE, Berthelot JM, et al. (2012) Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the Autoimmunity and Rituximab Registry. *Arthritis Care Res* 64, 331–39
- Molloy ES, Calabrese LH. (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. *Arthritis Rheum* 64, 3043–51
- Mahr A, Heijl C, Le Guenno G, Faurischou M. (2013) **ANCA-associated vasculitis** and malignancy: current evidence for cause and consequence relationships. *Best Pract Res Clin Rheumatol* 27, 45–56
- LaRock CN, Cookson BT (2013) **Burning Down the House**: Cellular Actions during Pyroptosis *PLOS Pathogens*. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868505/>
<http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1003793>

Saviola G et al. (2013) **Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induce a significant additive value-a 24 month single-blind pilot studie.** Rheumatol Int. 33(11), 2833-8. doi: 10.1007/s00296-013-2822-0.
<http://www.ncbi.nlm.nih.gov/pubmed/23864141>

van Dijkhuizen P, Wulffraat NM (2014) **Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.** Pediatric Rheumatology 12, 51 doi:10.1186/1546-0096-12-51 <http://www.ped-rheum.com/content/12/1/51>
„Interesting candidate predictors were found, especially for MTX efficacy. However, most of these were not validated. This should be the goal of future efforts. A clinically relevant way to validate the predictors is by means of creating a clinical prediction model.“

- ➔ **Immunität** http://www.erlebnishaft.de/danger_model.pdf
- ➔ **Antizytokine, Antichemokine** <http://www.kabilahsystems.de/antizyt-chem.pdf>
- ➔ **S.a. Protozoen- / Krebsstammzell- Therapie**
<http://www.xerlebnishaft.de/krebsstammzelltherapie.pdf>

Bernt - Dieter Huismans 2013. Letzte Revision November 2016 www.Huismans.click 
Back to top: <http://www.xerlebnishaft.de/immunsuppression.pdf>